T1	Participants 695 793	Of 750 participants who received at least one dose of study treatment, 123 (16%) were HIV-infected
T2	Participants 1042 1055	participants,
T3	Participants 1195 1220	HIV-infected participants
T4	Participants 1308 1337	non-HIV-infected participants
T5	Participants 1374 1394	HIV-infected persons
T6	Participants 1558 1578	HIV-infected persons
